Fig. 1

VEGFR-2 expression and phosphorylation patterns in HMECs and HUVECs with VEGF or SU5416. a Quantification for protein levels of VEGFR-2 in HMECs treated with either no treatment (NT) control media, 25 ng/mL VEGF (V), 3 µM SU5416 (SU), or both VEGF and SU5416 (V + SU) for 72 h. b Quantified Western blot analyses for phosphorylated VEGFR-2 at Y1054/Y1059 and Y1214 normalized to total VEGFR-2 values for each HMEC sample. c Quantification for protein levels of VEGFR-2 in HUVECs treated with either no treatment (NT) control media, 25 ng/mL VEGF (V), 3 µM SU5416 (SU), or both VEGF and SU5416 (V + SU) for 72 h. d Quantified Western blot analyses for phosphorylated VEGFR-2 at Y1054/Y1059 and Y1214 normalized to total VEGFR-2 values for each HUVEC sample. For all images, Western blot quantifications were normalized to β-actin, while phosphorylation quantifications being double-normalized to total VEGFR-2. *p < 0.05 compared to NT, ^p < 0.05 compared to V, #p < 0.05 compared to SU. Data shown as average + SEM, n = 6 for a and c, n = 3 for b and d. Group d was compared with Kruskal–Wallis test, followed by post hoc Dunn’s tests. Groups a–c were compared with ANOVA, followed by post hoc Tukey HSD tests